The ligand N-phenyl-N'-(2-thiazolyl) thiourea (LH) has been prepared from reaction of phenyl isothiocyanate with 2-aminothiazol. Treatment of deporotonated ligand (LH) with sodium tetrachloro palladate(II) afforded [Pd(L)(2)] complex 3. Reaction of complex 3 with [bis(diphenylphosphino) methane, dppm], [1,2-bis(diphenylphosphino)ethane, dppe] and [1,3-bis(diphenylphosphino)propane, dppp] afforded the mixed ligand complexes of the type [Pd(II)L-2(Ph2P(CH2) PPh2)], {where n = 1, dppm, n = 2, dppe or n = 3, dppp) 4-6, respectively. Further, complexes 4-6 have been treated with some transition metal salts to give homo- and heterobimetallic complexes 7-21 of the types: [(Ph2P(CH2)(n)PPh2) Pd (II)-mu-L2M'(II)X-m] and RPh2P(CH2)(n)PPh2)Pd(II)-mu-L2M'(II)X-m xH(2)O] (where n = 1, 2, or 3, M' = Pd(II), Ni(II), Mn(II), Co (II) or Cu (II) and X = Cl-, m = 2). The ligand and the prepared complexes have been characterized by elemental analysis, molar conductivity, magnetic susceptibility, FTIR, UV-Vis, H-1-P-31{H-1} NMR and mass spectroscopy. Some of these complexes have been assayed for their inhibition activity against human rhabdomyosarcoma (RMS) cell line. Interestingly, compound 19 exhibited a significant cytotoxicity inhibition activity similar to 90% for RMS cell line, suggesting being a new lead in the development of human muscle anticancer agent. All the compounds have been screened for their antibacterial activity against S. aureus and E. coli bacterium.